The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RA Capital’s largest new positions are Dyne Therapeutics, a clinical-stage biotech company that is innovating muscle-targeted therapeutics for genetic diseases, and Edgewise Therapeutics, a muscle disease biopharmaceuticals company. They rank 16th and 18th, respectively, in the U.S. portfolio.
They added during the rise here , the rise before the add was from the $5.85 low November to the $36 notice of adding April .
They have inside knowledge .
5.85 to 36 = 500 %
What a timely top up buy in Janux Therapeutics was $52.65 on 12/4/2024 it was up 10 times from 9th November 2023 when $5.85 a 5 year low , they increased position by 15 % last few weeks when price was around $36 1/4/2024.
36 to 52.65 = 46%
April 23, 2024
The biopharma specialist has made a flurry of major new purchases in recent weeks.
Biopharma hedge funds have been on a buying spree the past several weeks. Many of them reported in regulatory filings that they have initiated positions of at least 5 percent in individual stocks or boosted positions to well in excess of 5 percent of outstanding shares.
No firm, however, has been nearly as aggressive as RA Capital Management. In just the past four weeks, it has filed seven initial 13G or 13D documents indicating new investments of 5 percent or more. It also filed amended documents saying it has added to positions in at least four companies that are now holdings of 5 percent or more. Two of the new positions currently rank among the firm’s top-18 holdings, and three stocks in which RA Capital increased existing stakes were catapulted into the firm’s top eight.
This flurry of activity is unusual among life sciences and biopharma hedge funds, which rarely shuffle their portfolio’s largest positions from quarter to quarter. They are generally more of a buy-and-hold crowd, betting on firms they believe have the next drugs with the potential to receive FDA approval. Of course, given these fledgling companies’ small market caps, it does not take much capital to reach the 5 percent that triggers a 13D or 13G filing.
RA Capital is headed by founder Peter Kolchinsky and managing partner Rajeev Shah. As Institutional Investor previously reported, its hedge fund is up 14 percent for the year through March.
With the recent transactions, three stocks have moved onto the firm’s top-ten list.
Janux Therapeutics is the firm’s fourth-largest long, representing 5.72 percent of RA Capital’s U.S. common stock assets after the stake was boosted by more than 15 percent. The hedge fund firm now owns about 20 percent of the total shares outstanding. It is no stranger to Janux, as it was a major venture capital shareholder before the company went public in 2021. Janux is designing T cell immunotherapies that will kill tumors without impacting healthy tissue.
89bio is the seventh-largest long since RA Capital expanded its stake by nearly 25 percent. The hedge fund now has more than 15 percent of the clinical-stage biopharmaceuticals company, which develops therapies for liver and cardiometabolic diseases.
And Tyra Biosciences is the eighth-largest long after the firm recently lifted its stake by about 45 percent. RA Capital now owns more than 25 percent of the total shares. Tyra describes itself as a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor biology.
Redmile Group, LLC
Sold out of these on 31/12 /2022 & Jazz pharmaceuticals 30/9/23 .
They still have a large holding in Scancell ( SCLP ) 29% which they increased by 12% 20/12/23 from previous 17%
Bought the rest of yesterdays small part of order for slightly less $2.5
The lesser price paid just about covering today's dealing cost.
Set last night dealt at USA open , could of got for $2.45.... 30 mins later down... 6pm 3% down at $2.46
Https://www.barchart.com/stocks/quotes/BLDP/opinion
Charts say 100 % Sell .
Good sight home page has news story's .
Wanted to buy today at year low $2.52 only 3 went through part of large order.
Sold the 27/12/22 buy of $4.5 for $ 5.5 on 13/6/23 did not post here.
Pressurized to see today's transaction must of been GTC order placed 6/3/24.
Odd as other day orders placed after this date , could of bought two lots same price those days .
That would of been annoying .
Mistake to buy back in this one after sold all out 25/6/21.
6 Analysts expect the price to increase by 54% to $5.69
BEP 8.9348
15/04/24 Buy $3.56 ( Double up )
10/08/23 Buy $ 7.1
04/03/22 Buy $ 14.78
10/01/22 Buy $ 19
06/01/22 Buy $ 20.15
These guys say its a sell.
https://www.barchart.com/stocks/quotes/PRTA/opinion
Margin call notes were moved to this site .
October 2022 here below .
October 2023 went below 500 again.
Today over 56,000 , after many withdrawals mortgage pay off.
Full notes below , not this thread.
but not able to see on 0TDF.L now .
Posted in: 0TDF.L
RE: Margin call notes
Thursday 13th October 2022
Bought some more again for *$21.9.
Target had been $23.. $21.9 had been day low just after open , $22.2 when seen at 4.30pm.
Been a good trader in the past.
Out at planned target $237
Not a lot more then the sale two days ago approx 3.5%
24 Analysts expect the price to decrease by 23%.
On 7th February 2023 the same analysts expected the price to decrease by 17% , price was $74.59 - 17% = $61.9 .
It did fall back to $50.14 by Mayday that was more then the -17% ( -32% )
They were correct then.
The low was $32.53 January 2023
20/9/21 my first buy $232 .. 2 years 6 months.
.
Sliced again at $229 the older target before the last slice on 26/2/23.
Last seen at this level Christmas 2021.
They were up 12% today's high after $236
Continued a constant rise since 23/2/23.
Coinbase is Monday's Stock of The Day as it surges past a buy point. Shares of the cryptocurrency exchange are running higher with other crypto stocks as the bitcoin price spiked to nearly $55,000 for the first time since November 2021.
Sliced at a lowed target of $190 ($229 ) up on day 17% that tranche sold at a loss as first 3 buys were 232 , 229 & 228 all at the end of September 2021.
But sale above the bep which has not changed since 21/12/23 at $95.6036.
Better to trade USA .
17 Analysts expect the price to increase by 4% but that was from the last days close $166 to $172.7.
After my last slice on 20/12/24 at $168... 28/12/24 they topped out at $186 before retracing to $121 by 24th January 2024 small lift back to $132 next few days , then a dip to the $117 the 5th February 2024 low.
I see I did try and buy at $160 last week 20th to 23rd February , in hindsight a good idea .
Had tried to sell at $195 on 16th February ( D chart does not show near that ? )
But in hindsight of today lucky I did not sell at $187 on quickly deleted order 27/12/23.
One of the two core holdings .
www.berkshirehathaway.com/2023ar/linksannual23.html
Share reached $70.11 on 29th January 2024.
Back to $56 today.
USA Shares easier to trade then UK.
First Republic shares fell 40% the day I rebought and went bust on Mayday.
Bought some more again for *$25.54.
Been a good trader in the past.
02/02/24 Sold $205.7 just after arriving home 4.40pm , failed at $205 past week , extra covered costs .
Made approx 32%
16/2/22 Sell order failed at $198.38 and on 11/1/24 $190 thank God.
26/11/21 Bought these at $156.
Over the 26 months they fell to $150 on 01/12/22 ,
$139 on 12/7/22
$135 30/9/22
$141 27/10/23.
Bouncing of those lows but highest before recently $198 15/2/22 ( only 2 months after my buy )
Bought some more for *$27.5
Noticed the best Total P/L +17,099.86 on my account .
This value refers to the sum of unrealised and realised profits and losses made on this instrument since the opening of your account.
Note : This value is computed using various data sources and is displayed for information purposes. If you wish to know the exact booking prices of your transactions, please refer to the "Account" tab.
This shares notes on the correct board of course.
Bought some more for *$28.1
Target was $31 failed for the last three weeks .
Closed $28.39 last seen September 2022.
Looks like another big loss .
Delisted shares on acc today.
EV maker Arrival's shares slump on Nasdaq delisting notice
Jan 29 (Reuters) - Arrival said it received a delisting and stock trading suspension notice from the Nasdaq, sending the British electric-vehicle company's shares down about 15% on Monday.
Trading in Arrival's stock will be suspended from Jan. 30, as per the letter.
The company, like other EV startups, has battled higher interest rates and production costs over the past year, as well as dwindling cash reserves due to a funding squeeze.
Arrival was reportedly in talks with accounting firm EY about acting as an administrator if the company could not secure funds, Sky News reported on earlier this month.
Many EV firms, including Lordstown Motors, Proterra and Sweden's Volta Trucks, have gone bankrupt as a tough economy weighs on demand and hinders access to capital.
Arrival previously received a notice of delisting from Nasdaq for not complying with listing rules due to a delay in filing its interim financial statements and failure to hold an annual shareholder meeting.
Reporting by Zaheer Kachwala in Bengaluru; Editing by Sriraj Kalluvila
All out.
29/1/24 Sell $286
Target Sell was *283.5 .. failed last week.
24/7/23 Buy back @ 225
Same as first buy but + £61.44 the dollar must of strengthen since January 2021.
19/7/23 Sold 235
24/2/23 Bought them back 160.59 ( mistake corrected )
1/2/23 Sold all for $169.3 ( maybe mistake ) as under the buy off $225
26/1/23 sell 162
5/12/22 buy 139
20/1/22 buy 225*
8/11/21 they were $305
0QYQ has its own page